Every patient showed measurable tumor shrinkage—a rarity in cancer medicine.
In the long human struggle against cancer, moments of near-total response are vanishingly rare — yet a trial presented this autumn offered oncologists something close to one. A novel bispecific antibody-drug conjugate called iza-bren, paired with the established lung cancer therapy osimertinib, produced measurable tumor shrinkage in every one of the 40 patients receiving the optimal dose, all of them carrying EGFR-mutated advanced lung cancer. The result, emerging from early-phase data, does not yet constitute proof of cure, but it opens a door that the field has long been trying to find.
- A 100% objective response rate in any cancer trial is so uncommon that it immediately reorders the conversation about what is possible in EGFR-mutated lung cancer.
- The combination works by attacking cancer cells through two simultaneous mechanisms — blocking EGFR signaling while delivering a toxic payload directly into tumor cells — a coordinated assault that neither drug achieves alone.
- The durability is what gives the result weight: 92.1% of patients remained progression-free at 12 months, and the median response duration had not yet been reached after nearly 13 months of follow-up.
- The cost is real — nearly all patients experienced blood-related toxicities including anemia, neutropenia, and thrombocytopenia, demanding close monitoring and active supportive care throughout treatment.
- Only 13% of patients discontinued due to side effects, a low rate for a regimen this potent, suggesting the toxicity burden, while significant, remains within the bounds of clinical manageability.
- Larger randomized trials now stand as the necessary next threshold — confirmation of overall survival benefit will determine whether this combination becomes the new standard of first-line care.
At a major lung cancer conference this fall, researchers presented trial results that oncologists rarely encounter: a two-drug combination that shrank tumors in every single patient treated at the optimal dose. The drugs were iza-bren — a first-in-class bispecific antibody-drug conjugate — and osimertinib, a well-established third-generation therapy. All 40 patients in the optimal-dose cohort carried EGFR mutations in their advanced lung tumors, and all responded.
Iza-bren is engineered to do two things at once: bind to both EGFR and HER3 proteins on cancer cells while delivering a toxic topoisomerase inhibitor directly into them. Paired with osimertinib, which blocks EGFR signaling through a separate pathway, the combination appears to attack the disease from multiple angles simultaneously. The trial enrolled 154 patients across dose levels, with 2.5 milligrams per kilogram emerging as the balance point between efficacy and tolerability.
Dr. Fei Zhou of Shanghai East Hospital, who presented the findings, highlighted not just the response rate but its staying power. At 12 months, 92.1% of optimal-dose patients remained free of disease progression. Neither the median duration of response nor the median progression-free survival had been reached at the time of analysis — a sign, with nearly 13 months of follow-up, that the benefit is holding.
The side effect burden was substantial and almost entirely blood-related. Anemia affected over 90% of patients; neutropenia and leukopenia occurred at similar rates; thrombocytopenia affected roughly three-quarters. Nausea, mouth sores, fatigue, and other effects were also common. Yet grade 3 or higher events proved manageable with dose adjustments and supportive care, and only 13% of patients stopped iza-bren due to toxicity — a low discontinuation rate for a combination this aggressive.
The current standard for EGFR-mutated advanced lung cancer is osimertinib alone or with chemotherapy. If a 100% response rate holds in larger trials, and if overall survival benefit follows, this combination could redefine what first-line treatment looks like for this patient population. Randomized confirmation remains the essential next step.
In a trial presented this fall at the International Association for the Study of Lung Cancer's annual conference, a two-drug combination achieved something oncologists rarely see: every single patient showed measurable tumor shrinkage. The drugs were iza-bren, a newly developed bispecific antibody engineered to attack cancer cells, paired with osimertinib, a well-established third-generation lung cancer medication. The patients all had the same genetic mutation—EGFR—in their tumors, and all had advanced disease that had spread locally or to distant sites. Among the 40 patients receiving the optimal dose of 2.5 milligrams per kilogram, the response rate was 100 percent.
Iza-bren represents a novel class of drug called an antibody-drug conjugate. It works by targeting two different proteins on cancer cells—EGFR and HER3—while simultaneously delivering a toxic payload, a topoisomerase I inhibitor, directly into those cells. When combined with osimertinib, which blocks EGFR signaling through a different mechanism, the two drugs appear to work in concert. The trial enrolled 154 patients across multiple dose levels, but the 2.5 milligram-per-kilogram dose emerged as the sweet spot, delivering both efficacy and tolerability.
Dr. Fei Zhou from Shanghai East Hospital, who presented the findings, emphasized the durability of the response. At 12 months of follow-up, 92.1 percent of patients in the optimal-dose cohort remained free from disease progression. The median duration of response—the point at which half the patients have relapsed—had not yet been reached at the time of analysis, nor had the median progression-free survival. With a median follow-up of just under 13 months, this suggests the benefit is holding steady, though longer observation will be needed to know how long these responses ultimately last.
The trade-off came in the form of side effects, nearly all of them blood-related. Anemia affected 91.9 percent of patients. Neutropenia and leukopenia, both reductions in infection-fighting white blood cells, occurred in 91.1 percent. Thrombocytopenia, a drop in platelets that help blood clot, affected 75.6 percent. These are serious toxicities that require close monitoring and supportive care—transfusions, growth factor injections, and other interventions. Beyond the blood counts, patients experienced nausea, mouth sores, loss of appetite, vomiting, diarrhea, weakness, liver enzyme elevations, low potassium, low albumin, weight loss, rash, and hair loss.
Yet the severity was manageable. Grade 3 or higher adverse events—the most serious category—could be controlled with supportive measures and dose adjustments. Only 13 percent of patients discontinued iza-bren because of side effects, a remarkably low discontinuation rate for a drug combination this potent. Dr. Zhou noted that the regimen proved tolerable enough to continue, suggesting the toxicity profile, while real, did not outweigh the clinical benefit.
For patients with EGFR-mutated advanced lung cancer, the current standard of care is osimertinib alone or in combination with chemotherapy. A 100 percent response rate, if confirmed in larger trials, would represent a meaningful advance. The fact that responses are durable at one year, and that most patients can tolerate the treatment, points toward a potential new first-line option. The next steps will be to confirm these results in a larger, randomized trial and to determine whether this combination can extend overall survival—the ultimate measure of benefit in cancer medicine.
Citações Notáveis
These results suggest that this combination could offer a potentially transformative first-line treatment option for EGFR-mutant NSCLC, and the regimen was manageable from a safety perspective.— Dr. Fei Zhou, Shanghai East Hospital
A Conversa do Hearth Outra perspectiva sobre a história
A 100% response rate sounds almost too good to be true. What does that actually mean for a patient?
It means their tumor shrank by at least 30 percent on imaging. It's a real, measurable change. But response rate and survival are different things—we don't yet know if this extends how long they live.
And the side effects—anemia in 92 percent of patients—that's almost everyone. How do you call that manageable?
Because manageable doesn't mean absent. It means doctors can treat it. Transfusions, injections to boost blood counts, close monitoring. The key is that only 13 percent quit the drug because of it. People tolerated it.
Why does this combination work better than osimertinib alone?
Osimertinib blocks one pathway. Iza-bren hits two proteins at once and delivers a toxin directly into the cell. It's like using two different locks on the same door, plus breaking the hinges.
The median progression-free survival hasn't been reached yet. What does that tell you?
That at 12.8 months, more than half the patients still haven't relapsed. It's a good sign, but it's early. We need to watch longer to know if this is truly transformative or just impressive in the short term.
Who benefits most from this?
Right now, only patients with EGFR mutations in their lung cancer. That's maybe 40 percent of lung cancer patients in Asia, fewer in the West. It's a precision medicine approach—not for everyone, but potentially life-changing for the right person.